A Study Evaluating TRIV-509 in Atopic Dermatitis
This research study is looking into a new medicine called TRIV-509 for people aged 18 to 75 who have moderate to severe eczema, also known as atopic dermatitis. The main goals are to find out if TRIV-509 can effectively treat eczema and if it's safe for patients to use. Participants will receive either TRIV-509 or a 'dummy' treatment (placebo) for 16 weeks. Afterwards, they will switch and receive the other treatment for another 16 weeks. This helps researchers compare the effects of the new medicine to the placebo directly in each person. The study will last for up to 57 weeks for each participant, including an initial check-up period.
At a glance
What is this study about?
This study is a medical research project focused on a new potential treatment for eczema, specifically moderate to severe atopic dermatitis, in adults. Atopic dermatitis is a common skin condition that causes dry, itchy, and inflamed skin. The new medicine being tested is called TRIV-509.
The main purpose of this study is to understand two important things: first, if TRIV-509 can help reduce the symptoms of moderate to severe eczema; and second, to check if the medicine is safe and doesn't cause too many side effects. By carefully studying the effects of TRIV-509, doctors hope to find better ways to manage this challenging skin condition.
In this type of study, some people will receive the new medicine, TRIV-509, while others will receive a 'placebo.' A placebo looks just like the real medicine but contains no active ingredients. This comparison is very important because it helps researchers know if any changes people experience are truly due to the new medicine or if they might have happened anyway. After a set period, participants will switch treatments, so everyone gets a chance to take both the active medicine and the placebo at different times.
Key takeaways
- Testing a new medicine (TRIV-509) for moderate to severe eczema in adults.
- Aims to check if it works and is safe.
- Participants will try both the new medicine and a dummy treatment (placebo) over time.
- The study lasts up to 57 weeks.
- Open to adults aged 18-75 with active eczema.
- Close medical monitoring throughout the study.
Who may be eligible?
To be part of this study, you need to be an adult between 18 and 75 years old. You must have eczema (atopic dermatitis) that is considered moderate to severe, meaning it's causing significant symptoms and is active at the time of the study.
There are certain reasons why you might not be able to join. For example, if you have other serious or uncontrolled health problems. Also, if you've recently used certain treatments for your eczema, such as strong creams, light therapy, or specific medicines that affect your immune system, you might need to wait a certain period before you can participate. This 'waiting period' is to make sure that any effects seen in the study are from TRIV-509 and not from previous treatments.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you between 18 and 75 years old?
- Do you have moderate to severe eczema (atopic dermatitis) that is active right now?
- Do you have any other serious or uncontrolled health conditions?
- Have you recently used strong eczema treatments like special creams, light therapy, or certain immune-modifying medicines?
What does participation involve?
If you decide to take part in this study, the total time commitment will be up to 57 weeks. This includes an initial check-up period that could last up to 30 days to make sure you meet all the requirements. During the main part of the study, you will receive either TRIV-509 or a dummy treatment (placebo) for 16 weeks, taking 4 doses of that treatment. Then, you will switch to the other treatment (the one you didn't get first) for another 16 weeks, also taking 4 doses. You will have regular visits to the clinic for assessments, which will likely include physical examinations, blood tests, and discussions about how you're feeling and how your eczema is changing. All study-related medication and assessments will be provided.
Potential risks and benefits
Locations (32)
- Triveni Bio Site #11Verified postcodeFountain Valley, United States
- Triveni Bio Site #4Verified postcodeSan Diego, United States
- Triveni Bio Site #3Verified postcodeMiami, United States
- Triveni Bio Site #6Verified postcodeIndianapolis, United States
- Triveni Bio Site #10Verified postcodeSouth Bend, United States
- Triveni Bio Site #1Verified postcodeCamp Hill, United States
- Triveni Bio Site #16Verified postcodeBellaire, United States
- Triveni Bio Site #5Verified postcodeDallas, United States
- Triveni Bio Site #8Verified postcodeSpokane, United States
- Triveni Bio Site #38Verified postcodePleven, Bulgaria
- Triveni Bio Site #39Verified postcodeSofia, Bulgaria
- Triveni Bio Site #13Verified postcodeAjax, Canada
Common questions
What is atopic dermatitis?
Atopic dermatitis is a common type of eczema that causes dry, itchy, and irritated skin. It often starts in childhood but can affect adults too.
What does 'moderate to severe' atopic dermatitis mean?
This means your eczema is causing significant symptoms that affect your daily life, and it's active when you join the study.
What is a placebo?
A placebo is a 'dummy' treatment that looks just like the real medicine but doesn't contain any active ingredients. It helps researchers compare the new medicine's effects.
Will I know if I'm getting the real medicine or the placebo?
No, neither you nor the study doctors will know who is getting which treatment during the main part of the study. This is called 'blinding' and helps keep the study fair.
How long will I be in the study?
Your total time in the study will be up to 57 weeks, including an initial check-up period of up to 30 days.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.